1. Home
  2. GNLX vs ASMB Comparison

GNLX vs ASMB Comparison

Compare GNLX & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GNLX
  • ASMB
  • Stock Information
  • Founded
  • GNLX 2001
  • ASMB 2005
  • Country
  • GNLX United States
  • ASMB United States
  • Employees
  • GNLX N/A
  • ASMB N/A
  • Industry
  • GNLX Biotechnology: Pharmaceutical Preparations
  • ASMB Biotechnology: Pharmaceutical Preparations
  • Sector
  • GNLX Health Care
  • ASMB Health Care
  • Exchange
  • GNLX Nasdaq
  • ASMB Nasdaq
  • Market Cap
  • GNLX 112.8M
  • ASMB 130.2M
  • IPO Year
  • GNLX 2023
  • ASMB 2010
  • Fundamental
  • Price
  • GNLX $3.09
  • ASMB $18.14
  • Analyst Decision
  • GNLX Strong Buy
  • ASMB Strong Buy
  • Analyst Count
  • GNLX 4
  • ASMB 3
  • Target Price
  • GNLX $17.75
  • ASMB $33.00
  • AVG Volume (30 Days)
  • GNLX 137.5K
  • ASMB 41.3K
  • Earning Date
  • GNLX 08-13-2025
  • ASMB 08-07-2025
  • Dividend Yield
  • GNLX N/A
  • ASMB N/A
  • EPS Growth
  • GNLX N/A
  • ASMB N/A
  • EPS
  • GNLX N/A
  • ASMB N/A
  • Revenue
  • GNLX N/A
  • ASMB $32,154,000.00
  • Revenue This Year
  • GNLX N/A
  • ASMB $0.04
  • Revenue Next Year
  • GNLX N/A
  • ASMB N/A
  • P/E Ratio
  • GNLX N/A
  • ASMB N/A
  • Revenue Growth
  • GNLX N/A
  • ASMB 148.33
  • 52 Week Low
  • GNLX $1.60
  • ASMB $7.75
  • 52 Week High
  • GNLX $5.89
  • ASMB $19.93
  • Technical
  • Relative Strength Index (RSI)
  • GNLX 56.10
  • ASMB 68.18
  • Support Level
  • GNLX $2.75
  • ASMB $17.45
  • Resistance Level
  • GNLX $3.17
  • ASMB $18.92
  • Average True Range (ATR)
  • GNLX 0.24
  • ASMB 0.87
  • MACD
  • GNLX -0.00
  • ASMB -0.05
  • Stochastic Oscillator
  • GNLX 56.94
  • ASMB 74.68

About GNLX Genelux Corporation

Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.

About ASMB Assembly Biosciences Inc.

Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.

Share on Social Networks: